Dr. Marnie Rose was 27 and in the first year of a pediatric medical residency at Children’s Memorial Hermann Hospital in Houston, Texas when she was diagnosed with a rare form of brain cancer.

Marnie courageously shared her story through the ABC reality series Houston Medical, which aired its final episode just five weeks before her death on August 23, 2002, from complications of the cancer. Her compelling story lives on, and has inspired those who knew her and have come to know her through the foundation established in her memory.

7:15 am  Registration and Continental Breakfast
8:00 Welcome and Inauguration
  • Dr. Ronald DePinho - Welcome
  • Dr. Richard Gorlick - Director of Pediatrics
  • Marnie Rose Foundation- Lanie Rose
  • The Scully Family
  • Dr. Soumen Khatua - Overview

Session #1: Immunotherapy in Pediatric Brain Tumors
Session Chairs: Daniel C. Bowers, MD and Mark R. Gilbert, MD
8:30  Overview- Immunotherapy in Pediatric Brain Tumors
Keynote Speaker: Mark R. Gilbert, MD
8:55  Targeting Brain Tumors with Genetically Engineered T Cells
Stephen M. Gottschalk, MD
9:10  Local Regulated IL-12 Expression for the Treatment of Brain Tumors in Children Including DIPG
Laurence J.N. Cooper, MD, PhD and Francois Lebel, MD
9:25  NK Cell in Brain Tumors
Dean Lee, MD, PhD
9:40  Immunomodulatory Effects of LSD1 Inhibition in DIPG and Translational Aspects
Joya Chandra, PhD
9:55  Panel Discussion
10:15 Break

Session #2: Molecular Targeted Therapy
Session Co-Chairs: Murali Chintagumpala, MD; Amar Gajjar, MD and Virginia L. Harrod, MD, PhD
10:30  Targeted Therapy in Pediatric Neuro Oncology
Keynote Speaker: Amar Gajjar, MD
10:55  Precision Neuro-Oncology: Clinical Genomics for Children with CNS Tumors
Donald W. Parsons, MD, PhD

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.
11:10 Targeting the Brain Tumor Methylome  
Vidya Gopalakrishnan, PhD

11:25 Genetic and Epigenetic Landscapes of Medulloblastoma Subgroups  
Paul A. Northcott, PhD

11:40 WHO Classification 2016: Update on Pediatric Tumors  
Greg Fuller, MD, PhD, AS

11:55 Adult Medulloblastoma: What We Know and What We Don’t Know  
Marta Penas-Prado, MD

12:15 pm Panel Discussion

12:30 Lunch (provided) and Photo Shoot

Session #3: Preclinical Models to Clinical Trials
Session Co-Chairs: Juan Fueyo-Margareto, MD and Vidya Gopalakrishnan, PhD

1:15 More Subgroups, More Models: Using Genomics and Epigenomics to Inform Brain Tumor Model Development  
Stephen C. Mack, PhD

1:35 A Comprehensive Panel of Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Pediatric Brain Tumors  
Xiao-Nan Li, MD, PhD

1:55 What Can We Learn from Genetic Models of DIPG?  
Oren Josh Becher, MD

2:15 Panel Discussion

2:30 Break

General Session
Session Co-Chairs: Leena Ketonen, MD, PhD; Susan L. McGovern, MD, PhD; David Sandberg, MD and Wafik Zaky, MBBCH

2:45 Direct Drug Delivery into the Fourth Ventricle of the Brain to Treat Recurrent Malignant Posterior Fossa Tumors  
David Sandberg, MD

3:00 Laser Interstitial Thermal Therapy for the Treatment of Brain Tumors  
Sujit S. Prabhu, MD

3:15 Evolving Surgical and Multidisciplinary Management Strategies of Pediatric Skull Base Cancers  
Shaan M. Raza, MD

3:30 Radiation Therapy for Pediatric Low Grade Glioma  
Mary McAleer, MD, PhD

3:45 Synaptic Toxicities of Radiation Therapy  
David R. Grosshans, MD, PhD

4:00 Neurocognitive Outcome Following Radiation for Pediatric Brain Tumors: Review and Emerging Directions  
Peter Stavinoha, PhD

4:15 Molecular Neuroimaging  
Dawid Schellingerhout, MD

4:30 Clinical Trials in NF  
John M. Slopis, MD

4:45 Discussion

5:10 Closing Remarks

5:15 pm Adjourn

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth. Photographing, audio taping and videotaping are prohibited.